SpeeDx is the developer of innovative clinical diagnostics to support improved patient outcomes.
SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management.
SpeeDx was founded in 2009. The company is headquartered in Eveleigh, New South Wales, Australia, with offices in London and the US, and distributors across Europe.
SpeeDx has developed a molecular diagnostics test portfolio, principally for infectious diseases, that provides both identification as well as therapeutic guidance capabilities. It's product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.
SpeeDx is backed by Northpond Ventures, Illumina Ventures and others. The company $15M in additional Series B equity investment on Feb 11, 2020. This brings SpaceDx's total funding to $34M to date.